These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

381 related articles for article (PubMed ID: 16330442)

  • 61. Optimal pre-emptive cytomegalovirus therapy threshold in a patient population with high prevalence of seropositive status.
    Damlaj M; Khalid F; Alahmari B; Alaskar A; Ghazi S; Johani S; AlSaedy A; Bosaeed M; Alhejazi A; Al-Zahrani M
    Curr Res Transl Med; 2020 Aug; 68(3):131-137. PubMed ID: 32620466
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Cytomegalovirus infection in hematologic malignancy settings other than the allogeneic transplant.
    Marchesi F; Pimpinelli F; Ensoli F; Mengarelli A
    Hematol Oncol; 2018 Apr; 36(2):381-391. PubMed ID: 28660653
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Evaluation of risk of symptomatic cytomegalovirus reactivation in myeloma patients treated with tandem autologous stem cell transplantation and novel agents: a single-institution study.
    Marchesi F; Pimpinelli F; Dessanti ML; Gumenyuk S; Palombi F; Pisani F; Romano A; Spadea A; Maschio M; Ensoli F; Mengarelli A
    Transpl Infect Dis; 2014 Dec; 16(6):1032-8. PubMed ID: 25369809
    [TBL] [Abstract][Full Text] [Related]  

  • 64. An evaluation of the role of NKG2C+ natural killer cells in protection from cytomegalovirus DNAemia early following allogeneic stem cell transplantation.
    Muñoz-Cobo B; Giménez E; Solano C; de la Cámara R; Nieto J; López J; Amat P; Garcia-Noblejas A; Navarro D
    J Med Virol; 2014 May; 86(5):806-11. PubMed ID: 24105728
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Valganciclovir versus valaciclovir for prevention of alemtuzumab-induced cytomegalovirus reactivation: what are the implications for routine clinical practice?
    Smolej L
    Blood; 2008 Sep; 112(5):2167. PubMed ID: 18725576
    [No Abstract]   [Full Text] [Related]  

  • 66. Cytomegalovirus reactivation in lymphoma and myeloma patients undergoing autologous peripheral blood stem cell transplantation.
    Massoud R; Assi R; Fares E; Haffar B; Charafeddine M; Kreidieh N; Mahfouz R; Kanj SS; El Zakhem A; Kharfan-Dabaja M; Bazarbachi A; El Cheikh J
    J Clin Virol; 2017 Oct; 95():36-41. PubMed ID: 28843110
    [TBL] [Abstract][Full Text] [Related]  

  • 67. [Clinical study of low cytomegalovirus viral load thresholds for preemptive antiviral therapy in hematopoietic cell transplant recipients].
    Li L; Wang Y; Yan CH; Huang XJ
    Zhonghua Nei Ke Za Zhi; 2018 Mar; 57(3):191-195. PubMed ID: 29518863
    [No Abstract]   [Full Text] [Related]  

  • 68. Human herpesvirus-6 DNAemia is a sign of impending primary CMV infection in CMV sero-discordant renal transplantations.
    Van Leer-Buter CC; Sanders JS; Vroom HE; Riezebos-Brilman A; Niesters HG
    J Clin Virol; 2013 Oct; 58(2):422-6. PubMed ID: 23938304
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Impact of cytomegalovirus DNAemia on overall and non-relapse mortality in allogeneic stem cell transplant recipients.
    Solano C; Giménez E; Piñana JL; Albert E; Vinuesa V; Hernández-Boluda JC; Amat P; Navarro D
    Transpl Infect Dis; 2017 Aug; 19(4):. PubMed ID: 28471073
    [TBL] [Abstract][Full Text] [Related]  

  • 70. High incidence of post-transplant cytomegalovirus reactivations in myeloma patients undergoing autologous stem cell transplantation after treatment with bortezomib-based regimens: a survey from the Rome transplant network.
    Marchesi F; Mengarelli A; Giannotti F; Tendas A; Anaclerico B; Porrini R; Picardi A; Cerchiara E; Dentamaro T; Chierichini A; Romeo A; Cudillo L; Montefusco E; Tirindelli MC; De Fabritiis P; Annino L; Petti MC; Monarca B; Arcese W; Avvisati G;
    Transpl Infect Dis; 2014 Feb; 16(1):158-64. PubMed ID: 24215479
    [TBL] [Abstract][Full Text] [Related]  

  • 71. An investigation on the relationship between the occurrence of CMV DNAemia and the development of invasive aspergillosis in the allogeneic stem cell transplantation setting.
    Giménez E; Solano C; Nieto J; Remigia MJ; Clari MÁ; Costa E; Muñoz-Cobo B; Amat P; Bravo D; Benet I; Navarro D
    J Med Virol; 2014 Apr; 86(4):568-75. PubMed ID: 24037906
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Treatment of cytomegalovirus infection after renal transplantation: experience from a single center in China.
    Li Y; Yan H; Xue WJ; Tian PX; Ding XM; Pan XM; Feng XS; Xiang HL; Hou J; Tian XH; Zheng J; Ding CG; Fan P; Liu HB
    Ann Transplant; 2013 Mar; 18():125-35. PubMed ID: 23792512
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Limited predictive value of real-time quantitative PCR cytomegalovirus monitoring in the blood. Fatal CMV pneumonia in an autologous stem cell transplant recipient previously treated with alemtuzumab.
    Halaburda K; Nasiłowska-Adamska B; Grabarczyk P; Szczepiński A; Szpila T; Warzocha K; Mariańska B
    Ann Transplant; 2007; 12(2):37-40. PubMed ID: 18173065
    [TBL] [Abstract][Full Text] [Related]  

  • 74. [The clinical evaluation of preemptive treatment of cytomegalovirus infection after allogeneic hematopoietic stem cell transplantation].
    Zhang P; Wang C; Jiang JL; Jiang Y; Yan SK; Yang J
    Zhonghua Nei Ke Za Zhi; 2009 Jul; 48(7):539-41. PubMed ID: 19957791
    [TBL] [Abstract][Full Text] [Related]  

  • 75. The impact of virus population diversity on the dynamics of cytomegalovirus DNAemia in allogeneic stem cell transplant recipients.
    Vinuesa V; Bracho MA; Albert E; Solano C; Torres-Puente M; Giménez E; González-Candelas F; Navarro D
    J Gen Virol; 2017 Oct; 98(10):2530-2542. PubMed ID: 28874227
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Lessons from the natural history of cytomegalovirus.
    Bowen EF; Griffiths PD; Davey CC; Emery VC; Johnson MA
    AIDS; 1996 Nov; 10 Suppl 1():S37-41. PubMed ID: 8970675
    [TBL] [Abstract][Full Text] [Related]  

  • 77. [Ganciclovir treatment failure in adult allogeneic hematopoietic stem cell transplant recipients with cytomegalovirus infection--a single centre experience].
    Vejražková E; Hubáček P; Kutová R; Plíšková L; Košťál M; Štěpánová V; Zavřelová A; Radocha J; Malá E; Žák P
    Epidemiol Mikrobiol Imunol; 2015 Sep; 64(3):160-8. PubMed ID: 26448304
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Pre-emptive antiviral therapy for active CMV infection in adult allo-SCT patients guided by plasma CMV DNAemia quantitation using a real-time PCR assay: clinical experience at a single center.
    Solano C; Muñoz-Cobo B; Giménez E; Remigia MJ; Amat P; Clari MA; Bravo D; Benet I; Montoro J; Navarro D
    Bone Marrow Transplant; 2013 Jul; 48(7):1010-2. PubMed ID: 23334275
    [No Abstract]   [Full Text] [Related]  

  • 79. Sirolimus exposure and the occurrence of cytomegalovirus DNAemia after allogeneic hematopoietic stem cell transplantation.
    Piñana JL; Perez-Pitarch A; Guglieri-Lopez B; Giménez E; Hernandez-Boluda JC; Terol MJ; Ferriols-Lisart R; Solano C; Navarro D
    Am J Transplant; 2018 Dec; 18(12):2885-2894. PubMed ID: 29603596
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Assessment of the efficacy and safety of pre-emptive anti-cytomegalovirus (CMV) therapy in HIV-infected patients with CMV viraemia.
    Mattioni S; Pavie J; Porcher R; Scieux C; Denis B; De Castro N; Simon F; Molina JM
    Int J STD AIDS; 2015 Apr; 26(5):306-12. PubMed ID: 24845948
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 20.